Two investigator-initiated trials received funding. The DAPA-PKD trial is led by Emily Cornec-Le Gal and Dominique Guerrin and will run in France.
The STOP-PKD trial is led by Roman Müller from Germany (PI) and Ron Gansevoort from the Netherlands (co-PI), running in Germany, the Netherlands, Austria, and Spain. These investigators received funding from the French and German governments respectively.
Both trials are designed as investigator-initiated trials testing in a double-blinded, randomized setting the protective effects of SGLT2 inhibitors on kidney function loss and kidney volume growth.